Core Viewpoint - Vanguard Health Care ETF (VHT) has lagged the broader market by 57 points over the past five years, yet long-term investors continue to hold it due to its defensive characteristics and consistent demand in healthcare spending, which remains stable even during economic downturns [2][4]. Group 1: Fund Overview - VHT holds over 500 healthcare positions, with top holdings including Eli Lilly (12.5%), Johnson & Johnson (8.8%), AbbVie (6.1%), Merck (4.6%), and UnitedHealth Group (3.9%) [2][8]. - The fund tracks the MSCI US Investable Market Index (IMI)/Health Care 25/50, providing broad exposure to the U.S. healthcare sector, from large pharmaceutical companies to small biotechs [6]. - VHT has a low expense ratio of 0.09% and a portfolio turnover of 4%, indicating a buy-and-hold strategy [7]. Group 2: Performance Analysis - Over the past decade, VHT returned approximately 158%, while the total U.S. stock market returned nearly 215%, highlighting a significant performance gap [9]. - In the last five years, VHT gained about 28%, compared to a 57% increase in the total market [10]. - Year-to-date in 2026, VHT is down about 5%, slightly worse than the broader market's 3% decline [10]. Group 3: Investment Rationale - VHT serves as a tactical sector sleeve for investors seeking dedicated healthcare exposure without the need to select individual stocks, making it suitable for diversified portfolios [13]. - The aging global population drives sustained demand for healthcare products and services, regardless of economic conditions [13]. - VHT offers genuine diversification across various sub-industries within healthcare, appealing to investors looking to tilt their portfolios towards this sector's growth potential [13]. Group 4: Risks and Considerations - The fund's concentration in top holdings, particularly Eli Lilly, creates sensitivity to single-stock performance, meaning setbacks in major companies can significantly impact the entire portfolio [14]. - Regulatory risks, such as drug pricing legislation and insurance market reforms, can affect VHT's largest holdings and overall performance [14]. - Despite its defensive label, VHT has underperformed the broader market over both five-year and ten-year periods, indicating that it may not fully cushion against market risks [14].